CBS-3595

CBS-3595 is a dual p38α MAPK/PDE-4 inhibitor with moderate nanomolar potency, favorable pharmacokinetics, and low plasma protein binding. Its anti-inflammatory efficacy, demonstrated by suppressing TNFα release in vivo, occurs at doses and systemic exposures significantly below toxicological thresholds, supporting its research utility in inflammatory disease models.